Nothing to stop NVO now. Just want for the obesity news.
I can't find any news online. Did the advisory committee release it's findings?
also: Nov 8 (Reuters) - Novo Nordisk A/S : * FDA advisory panel acting chairperson says panel members generally agree that signal of cardiovascular risk was seen for Novo nordisk's
degludec insulin, and that it "may or may not be real" risk
Some findings for sure. Nov 8 (Reuters) - Novo Nordisk A/S : * Hypoglycemia risk of Novo nordisk's degludec insulin in trials did
not appear significantly higher or lower than oher insulins -- chair of FDA
advisory panel * Balance seemed reasonable between efficacy and hypoglycemia in studies of
degludec - chair of FDA advisory panel * 24-hr half life of degludec makes it unique in terms of long, stable
duration, dosing flexibility - chair of FDA advisory panel
Sentiment: Strong Buy